Important Notice The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR and NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the i

Results to be read in conjunction with notes from the Company s Half Year Report and previous year s Annual Report, both published in compliance with ASX listing rule 4.2A. 9 Exciting year ahead Continued scale up of manufacturing and expanding our cell collection network Phase 2 results in ovarian cancer trial: 3Q CY13 immune monitoring profile Q4 CY13 PFS and OS data Continued rollout of CANVAS CVac opportunities for other cancer targets in phase 2 / POC trials 10

Results to be read in conjunction with notes from the Company s Half Year Report and previous year s Annual Report, both published in compliance with ASX listing rule 4.2A. 8 Income statement for the Half Year ended 31 December 2012* (unaudited) 31 December 2012 31 December 2011 A$ A$ OTHER INCOME Total other income 2,079,220 3,031,479 EXPENSES Depreciation and amortisation (118,138) (78,922) Research and development and intellectual property (7,279,338) (7,515,131) Corporate administrative expenses (2,607,964) (3,281,424) Changes in fair value of derivative financial instruments (37,190) (1,470,049) Loss before income tax (7,963,410) (9,314,047) Income tax expense (66,996) Loss for the half year (8,030,406) (9,314,047) *according to International Financial Reporting Standards (IFRS).

This presentation should not be relied on as a recommendation or forecast by Prima BioMed. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. 2 CVac Overview MNCs (white blood cells) taken from the patient by apheresis and sent to lab MNCs separated and matured to decdritic cells (DCs) with growth factors DCs are pulsed with the antigen Mannan Mucin 1 Fusion Protein (MFP) Mucin 1 antigen is internalized by the DCs The DCs washed, formulated, and frozen as 1ml vials Manufacturing of CVac Mechanism after injection Mucin 1 is overexpressed on ovarian cancer cells Cvac administered as 4 intradermal injections at each dose CVac activates CD8+ T cells specific to mucin 1 T cells target mucin 1 overexpressed on cancer cells T cells kill cancer cells 3 Company strategy Developing personalized immunocellular therapeutics for cancer Establishment of a robust global supply, logistics, and manufacturing platform leads to clinical and commercial success Video review of Prima s manufacturing is available at http://primabiomed.com.au/movies/movie_5.php Goals: monetize our assets through commercial product partnerships or licenses; increase value through continued investment in our operational platform and deepen our product pipeline 4 Manufacturing development Scaled up manufacturing of the mucin antigen (M FP) Achieved comparability of product manufacturing in three global facilities (Australia, USA, Germany); demonstrates our capability to transfer the technology into new facilities and it paves the way for future scale up into larger facilities when needed Implemented automated logistics management software coordinates manufacturing facilities, dozens of cell collections centers, hundreds of hospitals, the couriers, our laboratories, and Prima s quality managers around the globe Customized and validated shipping materials for CVac to allow for greater flexibility in the shipping timelines for CVac Inspected and approved 45 cell collection centers that will be able to collect blood product for making CVac across 13 countries; plan for 52 cell collection centers in 15 countries integrated into our quality system through CY 2013 Planning for careful scale up of production capacity from 63 patient trial to nearly 1000 patient trial 5 Clinical development ovarian cancer Focus of Prima s development has been on newly diagnosed, stage III/IV, epithelial ovarian cancer patients who achieve remission after standard first line debulking surgery and platinum/taxane chemotherapy Significant unmet medical need and low levels of potential competition EOC is receptive to immunotherapy approaches Targeting patients with low tumor burden reasonably intact immune system 6 Clinical trials ovarian cancer CAN 003: positive interim data reported in October November 2012: Trend of improved PFS in CVac patients CVac induces a mucin 1 specific t cell response CAN 003: upcoming data for all 63 patients: Final immune monitoring data in 3 quarter of CY 2013 Final PFS and initial OS data in 4 quarter of CY 2013 CAN 004 (CANVAS): status update: Underway in 4 countries and 26 clinical sites Controlled rollout through 2013 7 th rd Financial results for the Half Year ended 31 December 2012* Loss after tax: A$ 8,030,406 Loss per basic and diluted share: 0.75 cents (A$ 0.0075 per share) Loss is down 13.78% to corresponding period last year: Loss after tax: A$ 9,314,047 Loss per basic and diluted share: 0.92 cents (A$ 0.0092 per share) G A expenses: appx A$ 2.6 million (down from A$ 3.3 million) R D expenses: appx A$ 7.3 million (down from A$ 7.5 million) Cash term deposits: appx A$ 28 million (does not include A$ 1.4 million accrued during the reporting period but received after the reporting period in February 2013) *according to International Financial Reporting Standards (IFRS).

Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Prima BioMed s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed s control.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of information. Please contact Prima BioMed and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034 First half year results for FY 2013 (period ended 31 December 2012) Supplemental Information for Prima BioMed Conference Call on March 7, 2013 1 Exhibit 99.1 Important Notice The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR and NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.